- Liquid crystal compound containing dimethylbenzene and difluoromethylenedioxy linking group and application thereof
-
The invention discloses a liquid crystal compound containing a dimethylbenzene and difluoromethyleneoxy linking group and application of the liquid crystal compound. The compound is as shown in formula I. In the molecular structure of the compound as show
- -
-
Paragraph 0088; 0091-0094; 0100; 0103-0106; 0112; 0115; ...
(2021/09/01)
-
- BIARYL DERIVATIVE AS GPR120 AGONIST
-
The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
- -
-
Paragraph 0181
(2017/11/17)
-
- A 2,6-difluoro-4-bromophenylacetic formyl chloride method for the preparation of (by machine translation)
-
The invention discloses a 2, the 6 [...] difluoro -4 the method for preparing [...] bromophenylacetic formyl chloride, relates to the technical field of organic synthesis, to 3, the 5 two fluoro bromobenzene [...], diisopropylamine, composite material, ca
- -
-
Paragraph 0018
(2016/11/17)
-
- NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN, ETC
-
The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
- -
-
-
- HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.
- -
-
Paragraph 0419
(2014/06/23)
-
- NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
-
The present invention provides compounds useful as C-met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of C-met kinase mediated diseases or disorders with them.
- -
-
-
- 5-ALKYNYL-PYRIMIDINES
-
The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
- -
-
Page/Page column 16-17
(2012/02/06)
-
- CHEMICAL COMPOUNDS
-
The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
- -
-
Page/Page column 203-204
(2010/07/10)
-
- INHIBITORS OF STEAROYL-COA DESATURASE
-
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
- -
-
-
- MODULATORS OF DOPAMINE NEUROTRANSMISSION
-
The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
- -
-
Page/Page column 43-44
(2009/12/05)
-
- Study on the compounds containing 19F and 10B atoms in a single molecule for the application to MRI and BNCT
-
Magnetic resonance imaging (MRI) and boron-neutron capture therapy (BNCT) are quite attractive techniques for diagnosis and treatment of cancer, respectively. In order to progress the study on both MRI and BNCT, the novel compounds containing 19/sup
- Hattori, Yoshihide,Asano, Tomoyuki,Niki, Yoko,Kondoh, Hirofumi,Kirihata, Mitsunori,Yamaguchi, Yoshihiro,Wakamiya, Tateaki
-
p. 3258 - 3262
(2007/10/03)
-
- SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF
-
Disclosed are compounds of the formula (I), wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents. Also disclosed are methods of using and making such compounds.
- -
-
Page/Page column 54
(2010/02/10)
-
- Exploring Structural Opportunities: The Regioflexible Substitution of 1,3-Difluorobenzene
-
To demonstrate the superiority of modern organometallic methods, the inexpensive starting material 1,3-difluorobenzene has been selectively converted into the three benzoic acids and all seven bromobenzoic acids containing the two fluorine atoms in homovicinal positions. The 2,6-difluorobenzoic acid (1) was prepared in a one-pot reaction consisting of direct metallation and carboxylation. The key step on the route to the bromobenzoic acid 4 was a deprotonation-triggered bromine migration from the 2- to the 4-position. All other products were attained through (2,6-difluorophenyl)triethylsilane (11). Consecutive deprotonation of the sites adjacent to the fluorine atoms, followed by appropriate electrophilic substitution, provided not only the acid 7 but also the dibromo and iodobromo derivatives 13 and 23. These in turn gave the isomers 14 and 24 upon base-mediated migration of the heaviest halogen, which made the acids 8 and 10 directly accessible. The regiocontrolled monodebromination of intermediate 14 afforded (4-bromo-2,6-difluoro)triethylsilane (15), which opened the route to the acids 3 and 5 (by carboxylation and protodesilylation) and to acid 9 (by carboxylation and bromodesilylation). Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.
- Schlosser, Manfred,Heiss, Christophe
-
p. 4618 - 4624
(2007/10/03)
-
- Regioselective ortho-lithiation of chloro and bromo substituted fluoroarenes
-
Deprotonation of fluoroarenes carrying chlorine or bromine as additional substituents occurs always at a fluorine adjacent position if accomplished with potassium tert-butoxide activated butyllithium or lithium 2,2,6,6-tetramethylpiperidide.
- Mongin, Florence,Schlosser, Manfred
-
p. 6551 - 6554
(2007/10/03)
-
